Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of tolebrutinib in multiple sclerosis
2023-503631-18-01Phase 3Authorised
- Sponsor
- Sanofi
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 50
01
Overview
Phase 3, open-label trial of tolebrutinib in multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) (4 arms), sponsored by Sanofi. Primary endpoints: Number of participants with adverse events and Number of participants with potentially clinically significant abnormalities. Planned start May 2024; status: authorised.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2023-503631-18-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503631-18-01.